

Edgar Filing: BIOMERICA INC - Form 10QSB

BIOMERICA INC  
Form 10QSB  
January 20, 2004

FORM 10-QSB  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

QUARTERLY REPORT UNDER SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934

For Quarter Ended November 30, 2003  
-----

Commission File No. 0-8765  
-----

BIOMERICA, INC.

-----  
(Exact name of registrant as specified in its charter)

Delaware

95-2645573

-----  
(State or other jurisdiction of  
incorporation or organization)

(I.R.S. Employer  
Identification No.)

1533 Monrovia Avenue, Newport Beach, California

92663

-----  
(Address of principal executive offices)

(Zip Code)

Registrant's telephone number including area code: (949) 645-2111  
-----

(Not applicable)

-----  
(Former name, former address and former fiscal year, if  
changed since last report.)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

Indicate by check mark whether the Registrant is an accelerated filer (as Defined in Rule 12b-2 of the Exchange Act).

Yes  No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: 5,752,431 shares of common stock as of January 14, 2004.

1

BIOMERICA, INC.

# Edgar Filing: BIOMERICA INC - Form 10QSB

## INDEX

### PART I

|         |   |       |
|---------|---|-------|
| Item 1. | Condensed Consolidated Financial Statements:  |       |
|         | Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - Three and six Months Ended November 30, 2003 and 2002..... | 3 & 4 |
|         | Condensed Consolidated Balance Sheet (unaudited) - November 30, 2003.....   | 5 & 6 |
|         | Condensed Consolidated Statements of Cash Flows (unaudited) - Six Months Ended November 30, 2003 and 2002.....                                  | 7     |
|         | Condensed Consolidated Statement of Changes in Shareholders' Equity (unaudited) - Six Months Ended November 30, 2003.....                       | 8     |
|         | Notes to Consolidated Financial Statements.....   | 9-18  |
| Item 2. | Management's Discussion and Analysis of Financial Condition and Selected Financial Data.....  | 19-21 |
| Item 3. | Quantitative and Qualitative Disclosures about Market Risk.....   | 21-22 |
| Item 4. | Controls and procedures.....  | 22    |
| PART II | Other Information.....  | 23    |
| Item 1. | Legal Proceedings.....  | 23    |
| Item 2. | Changes in Securities and Use of Proceeds.....  | 23    |
| Item 3. | Defaults upon Senior Securities.....  | 23    |
| Item 4. | Submission of Matters to a Vote of Security Holders.....  | 23    |
| Item 5. | Other Information.....  | 23    |
| Item 6. | Exhibits and Reports on Form 8-K.....   | 23    |
|         | Signatures.....   | 24    |

PART I - FINANCIAL INFORMATION  
SUMMARIZED FINANCIAL INFORMATION  
ITEM 1. FINANCIAL STATEMENTS

BIOMERICA, INC.  
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  
AND COMPREHENSIVE LOSS (UNAUDITED)

Edgar Filing: BIOMERICA INC - Form 10QSB

|   | Six Months Ended<br>November 30, |              |
|---|----------------------------------|--------------|
|   | 2003                             | 2002         |
|   | -----                            | -----        |
| Net sales .....   | \$ 4,434,215                     | \$ 4,226,038 |
| Cost of sales .....   | 3,137,829                        | 2,952,354    |
| Gross profit .....  | 1,296,386                        | 1,273,684    |
| Operating Expenses:   |                                  |              |
| Selling, general and administrative .....   | 1,594,873                        | 1,457,869    |
| Research and development .....  | 141,753                          | 110,206      |
|   | -----                            | -----        |
|   | 1,736,626                        | 1,568,075    |
|   | -----                            | -----        |
| Operating loss from continuing operations .....   | (440,240)                        | (294,391)    |
|   | -----                            | -----        |
| Other Expense (income):   |                                  |              |
| Interest expense .....  | 15,376                           | 17,700       |
| Other income, net .....   | (33,258)                         | (51,922)     |
|   | -----                            | -----        |
|   | (17,882)                         | (34,222)     |
|   | -----                            | -----        |
| Loss from continuing operations, before minority interest<br>in net loss of consolidated subsidiaries and<br>income taxes ..... | (422,358)                        | (260,169)    |
| Minority interest in net gain (losses) of consolidated sub..  | 93,819                           | (17,867)     |
|   | -----                            | -----        |
| Loss from continuing operations, before income taxes .....  | (328,539)                        | (278,036)    |
| Income tax expense .....  | --                               | 1,794        |
|   | -----                            | -----        |
| Net loss from continuing operations .....   | (328,539)                        | (279,830)    |

3

BIOMERICA, INC.  
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  
AND COMPREHENSIVE LOSS - Continued (UNAUDITED)

|   | Six Months Ended<br>November 30, |        |
|---|----------------------------------|--------|
|   | 2003                             | 2002   |
|   | -----                            | -----  |
| Discontinued operations:                              |                                  |        |
| Income (loss) from discontinued operations, net ..... | (2,944)                          | 38,531 |

Edgar Filing: BIOMERICA INC - Form 10QSB

|   |              |           |
|---|--------------|-----------|
| Net loss .....  | (331,483)    | (318,361) |
| Other comprehensive gain (loss), net of tax                     |              |           |
| Unrealized gain (loss) on available-for-sale securities .....   | 22,362       | (1,757)   |
| Comprehensive loss .....  | \$ (309,121) | (320,118) |
| Basic net loss per common share:                                |              |           |
| Net loss from continuing operations .....                       | \$ (.06)     | \$ (.05)  |
| Net loss from discontinued operations .....                     | (.00)        | (.01)     |
| Basic net loss per common share .....                           | \$ (.06)     | \$ (.06)  |
| Diluted net loss per common share                               |              |           |
| Net loss from continuing operations .....                       | \$ (.06)     | \$ (.05)  |
| Net loss from discontinued operations .....                     | (.00)        | (.01)     |
| Diluted net loss per common share .....                         | \$ (.06)     | \$ (.06)  |
| Weighted average number of common and common equivalent shares: |              |           |
| Basic and diluted .....   | 5,675,890    | 5,208,818 |

The accompanying notes are an integral part of these statements.

4

BIOMERICA, INC.

CONDENSED CONSOLIDATED BALANCE SHEET (UNAUDITED)

|  | November 30,<br>2003 |
|--|----------------------|
|  | -----                |
| Assets   |                      |
| Current Assets   |                      |
| Cash and cash equivalents .....  | \$ 296,939           |
| Available for-sale securities .....                                      | 35,474               |
| Accounts receivable, less allowance for doubtful accounts of \$126,053.. | 1,355,874            |
| Inventories, net of reserve of \$187,371 .....                           | 2,655,486            |
| Notes receivable .....   | 1,619                |
| Prepaid expenses and other .....   | 175,570              |
|  | -----                |
| Total Current Assets .....   | 4,520,962            |
| Inventory, non-current .....   | 26,000               |

Edgar Filing: BIOMERICA INC - Form 10QSB

|   |             |
|---|-------------|
| Property and Equipment, net of accumulated depreciation and amortization .. | 593,427     |
| Intangible assets, net of accumulated amortization .....                    | 50,831      |
| Other Assets .....  | 62,904      |
|   | -----       |
|   | \$5,254,124 |
|   | =====       |

The accompanying notes are an integral part of these statements.

5

BIOMERICA, INC.

CONDENSED CONSOLIDATED BALANCE SHEET - Continued (UNAUDITED)

|  |                      |
|--|----------------------|
|  | November 30,<br>2003 |
|  | -----                |
| Liabilities and Shareholders' Equity   |                      |
| Current Liabilities  |                      |
| Line of credit .....   | \$ --                |
| Accounts payable and accrued liabilities .....   | 1,115,202            |
| Accrued compensation .....   | 491,226              |
| Current portion of shareholder loan .....  | 86,400               |
| Net liabilities from discontinued operations .....   | 367,299              |
|  | -----                |
| Total Current Liabilities .....  | 2,060,127            |
| Shareholder loan .....   | 237,185              |
|  | -----                |
| Total Liabilities .....  | 2,297,312            |
|  | -----                |
| Minority interest .....  | 2,058,422            |
|  | -----                |
| Shareholders' Equity   |                      |
| Common stock, \$0.08 par value authorized 25,000,000 shares,<br>subscribed or issued and outstanding 5,752,431 ..... | 460,193              |
| Additional paid-in-capital .....   | 17,211,165           |
| Accumulated other comprehensive gain .....   | 12,705               |
| Accumulated deficit .....  | (16,785,673)         |
|  | -----                |
| Total Shareholders' Equity .....   | 898,390              |
|  | -----                |
| Total Liabilities and Equity .....   | \$ 5,254,124         |
|  | =====                |

## Edgar Filing: BIOMERICA INC - Form 10QSB

The accompanying notes are an integral part of these statements.

6

### BIOMERICA, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

| For the six months ended November 30,  | 2003         |
|--|--------------|
|  |              |
| Cash flows from operating activities:  |              |
| Net loss from continuing operations .....  | \$ (328,463) |
| Adjustments to reconcile net loss to net cash<br>(used in) provided by operating activities: |              |
| Depreciation and amortization .....  | 57,449       |
| Minority interest in net loss of consolidated<br>Subsidiary .....                            | (93,819)     |
| Common stock, warrants and options issued for services<br>rendered .....                     | 55,172       |
| Provision for losses on accounts receivable .....  | 6,008        |
| Provision for losses on inventory .....  | 45,000       |
| Changes in current assets and liabilities:   |              |
| Accounts Receivable .....  | 301,354      |
| Inventories .....  | (51,554)     |
| Prepaid expenses and other current assets .....  | (5,766)      |
| Accounts payable and other accrued liabilities .....   | (164,932)    |
| Accrued compensation .....   | 158,326      |
| Net cash (used in) provided by operating activities .....                                    | (21,225)     |
| Cash flows from investing activities:  |              |
| Purchases of property and equipment .....  | (244,948)    |
| Other assets .....   | (19,504)     |
| Purchases of intangibles .....   | --           |
| Net cash used in investing activities .....  | (264,452)    |
| Cash flows from financing activities:  |              |
| Change in minority interest .....  | 6,180        |
| Increase (decrease) in shareholder loan .....  | 20,035       |
| Private placement, net of offering costs .....   | 30,500       |
| Exercise of stock options .....  | 2,000        |
| Decrease in line of credit .....   | (426)        |
| Net cash provided by (used in) financing activities .....                                    | 58,289       |
| Net cash used in discontinued operations .....   | (840)        |
| Net (decrease) increase in cash and cash equivalents .....                                   | (228,228)    |

Edgar Filing: BIOMERICA INC - Form 10QSB

|  |            |
|--|------------|
| Cash at beginning of period .....  | 525,167    |
|  | -----      |
| Cash at end of period .....  | \$ 296,939 |
|  | =====      |
| Supplemental disclosures on non-cash financing activity  |            |
| Issuance of common stock at market value in exchange for<br>settlement of accrued wages and shareholder loan ..... | \$ 20,000  |
|  | =====      |

The accompanying notes are an integral part of these statements.

7

BIOMERICA, INC.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY  
FOR THE SIX MONTHS ENDED November 30, 2003

|  | Common Stock           |            |                                  | Common Stock<br>Subscribed |          | Accumul<br>Other<br>Compreh<br>Gain (L |
|--|------------------------|------------|----------------------------------|----------------------------|----------|--|
|  | Number<br>of<br>Shares | Amount     | Additional<br>Paid-in<br>Capital | Shares                     | Amount   |  |
| Balance at<br>May 31, 2003   | 5,522,431              | \$ 441,793 | \$ 17,117,393                    | 18,000                     | \$ 4,500 | \$ (                                   |
| Exercise of stock<br>Options   | 10,000                 | 800        | 1,200                            |                            |          |  |
| Change in<br>unrealized<br>gain on available<br>for sale securities  |                        |            |                                  |                            |          | 2                                      |
| Net proceeds from<br>private placement   | 220,000                | 17,600     | 37,400                           | (18,000)                   | (4,500)  |  |
| Compensation<br>expense related<br>to the fair<br>value of common stock<br>and warrants<br>issued to employees<br>in excess of con-<br>sideration received |                        |            | 55,172                           |                            |          |  |
| Net loss   |                        |            |                                  |                            |          |  |
| Balance at<br>November 30, 2003  | 5,752,431              | \$ 460,193 | \$ 17,211,165                    | --                         | --       | \$ 1                                   |

## Edgar Filing: BIOMERICA INC - Form 10QSB

The accompanying notes are an integral part of these statements.

8

### NOTES TO FINANCIAL STATEMENTS (UNAUDITED)

November 30, 2003

- (1) Reference is made to Note 2 of the Notes to Consolidated Financial Statements contained in Biomerica, Inc.'s (the "Company") Annual Report on Form 10-KSB for the fiscal year ended May 31, 2003, for a summary of significant accounting policies utilized by the Company.

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP"), requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the report amounts of revenues and expenses during the reporting period. Significant estimates made by Biomerica's and Lancer's management include, but are not limited to, allowances for doubtful accounts, allowances for sales returns, valuation of inventories, realizability of property and equipment through future operations and realizability of deferred tax assets. Actual results could materially differ from those estimates.

- (2) As of November 30, 2003, the Company had cash and available-for-sale securities in the amount of \$332,413 and working capital of \$2,460,835. Cash and working capital totaling \$224,237 and \$2,477,013, respectively, relates to the Lancer subsidiary. Lancer's line of credit restricts Biomerica's ability to draw on Lancer's resources and, as such, said cash, working capital and equity are not available to Biomerica.

The Company has suffered substantial recurring losses from operations over the last couple of years. The Company has funded its operations through debt and equity financings, and may have to do so in the future. ReadyScript operations were discontinued in May 2001 and Allergy Immuno Technologies, Inc. was sold in May 2002. ReadyScript and Allergy Immuno Technologies were previously contributors to the Company's losses. The Company has reduced operating costs through certain cost reduction efforts and plans to concentrate on its core business in Lancer and Biomerica to increase sales. There can be no assurance that the Company will be able to become profitable, generate positive cash flow from operations or obtain the necessary equity or debt financing to fund operations in the future. Should the Company be unable to reduce costs adequately or should the Company be unable to secure additional financing, the result for the Company could be the inability to continue operations.

The Company will continue to have limited cash resources. Although the Company's management recognizes the imminent need to secure additional financing there can be no assurance that the Company will be successful in consummating any such transaction or, if the Company does consummate such transaction, that the terms and conditions of such financing will not be unfavorable to us.

Our independent certified public accountants have concluded that these factors, among others, raise substantial doubt as to the Company's ability



## Edgar Filing: BIOMERICA INC - Form 10QSB

to continue as a going concern for a reasonable period of time, and have, therefore modified their audit report on the Company's annual consolidated financial statements as of and for the year ended May 31, 2003, in the form of an explanatory paragraph describing the events that have given rise to this uncertainty. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result should the Company operating.

9

These consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has operating and liquidity concerns due to historically reporting net losses and negative cash flows from operations. Biomerica's shareholder's line of credit expired September 13, 2003. The unpaid principal and interest of \$337,835 was converted into a note payable bearing interest at 8% and payable in monthly installments over four years. The monthly payments required to pay the loan off in four years would be \$8,248. The Company is currently making payments of \$7,200 per month. The terms of the note are currently being negotiated. The note is secured by inventory and accounts receivable of Biomerica.

During the quarter ended November 30, 2003, the Company's operations used cash of \$21,225. This compares to cash provided by operations of \$363,596 in the same period in the prior fiscal quarter. Cash provided by financing activities was \$58,289, which resulted in part from a private placement at Biomerica of \$30,500, an increase in shareholder loan of \$20,035, exercise of stock options of \$2,000 and change in minority interest of \$6,180.

- (3) In December 2002, the FASB issued FAS No. 148, "Accounting for Stock-Based Compensation - Transition And Disclosure," which amended FAS No. 123 "Accounting for Stock-Based Compensation." The new standard provides alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. Additionally, the statement amends the disclosure requirements of FAS No. 123 to require prominent disclosures in the annual and interim financial statements about the method of accounting for stock-based employee compensation and the effect of the method used on reported results. This statement is effective for financial statements for fiscal years ending after December 15, 2002. In compliance with FAS No. 148, we have elected to continue to follow the intrinsic value method in accounting for our stock-based employee compensation plan as defined by APB No. 25, "Accounting for Stock Issued to employees."

The Black Sholes option valuation model was developed for use in estimating the fair value of traded options which have no vesting restrictions and are fully transferable. In addition, option valuations models require the input of highly subjective assumptions including the expected stock price volatility. Because the Company's employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management's opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. For purposes of pro forma disclosure, the estimated fair value of the options is amortized to expense over the options vesting period. Adjustments are made for options forfeited prior to vesting. The effect on compensation expense, net loss, and net loss per common share had compensation costs for the Company's stock option plans been determined based on a fair value at the date of grant consistent with the provisions

## Edgar Filing: BIOMERICA INC - Form 10QSB

of SFAS 148, for the six months and quarter ended November 30 is as follows:

| November 30,   | Six Months Ended |              | Three Months Ended |              |
|--|------------------|--------------|--------------------|--------------|
|  | 2003             | 2002         | 2003               | 2002         |
| -----  |                  |              |                    |              |
| Net loss from continuing operations, as reported   | \$ (328,539)     | \$ (279,830) | \$ (110,576)       | \$ (168,461) |
| Plus: Stock-based employee compensation expense included in reported net loss            | 55,172           | 32,364       | 7,092              | 65,818       |
| Less: Stock-based employee compensation expense determined using fair value based method | (12,575)         | (24,288)     | (6,269)            | (12,144)     |
| -----  |                  |              |                    |              |
| Net loss from continuing operations, pro forma   | \$ (285,942)     | \$ (271,754) | \$ (109,753)       | \$ (114,787) |
| =====  |                  |              |                    |              |
| Pro forma net loss from continuing operations per share - basic                          | \$ (0.03)        | \$ (0.02)    | \$ (.02)           | \$ (.03)     |
| =====  |                  |              |                    |              |
| Pro forma net loss from continuing operations per share - diluted                        | \$ (0.03)        | \$ (0.02)    | \$ (.02)           | \$ (.03)     |
| =====  |                  |              |                    |              |

10

(4) The following summary presents the options granted, exercised, expired, and outstanding as of November 30, 2003:

|                               | Number of Options |              |           | Weighted               |
|-------------------------------|-------------------|--------------|-----------|------------------------|
|                               | Employee          | Non-employee | Total     | Average Exercise Price |
|                               | -----             | -----        | -----     | -----                  |
| Outstanding May 31, 2003      | 990,386           | 75,000       | 1,065,386 | \$0.99                 |
| Granted                       | --                | --           | --        | 0.00                   |
| Exercised                     | --                | (10,000)     | (10,000)  | 0.20                   |
| Expired                       | (2,250)           | --           | (2,250)   | 0.85                   |
| Cancelled                     | (3,000)           | --           | (3,000)   | 0.40                   |
|                               | -----             | -----        | -----     | -----                  |
| Outstanding November 30, 2003 | 985,136           | 65,000       | 1,050,136 | \$1.00                 |
|                               | =====             | =====        | =====     | =====                  |

|  | Number of Warrants |              |       | Weighted               |
|--|--------------------|--------------|-------|------------------------|
|  | Employee           | Non-employee | Total | Average Exercise Price |
|  | -----              | -----        | ----- | -----                  |

Edgar Filing: BIOMERICA INC - Form 10QSB

|                   |           |           |           |        |
|-------------------|-----------|-----------|-----------|--------|
| Outstanding       |           |           |           |        |
| May 31, 2003      | 1,285,688 | 1,131,746 | 2,417,434 | \$2.79 |
| Granted           | 170,000   | 32,000    | 202,000   | 0.25   |
| Exercised         | --        | --        | --        | 0.00   |
| Expired           | --        | --        | --        | 0.00   |
|                   | -----     | -----     | -----     | -----  |
| Outstanding       |           |           |           |        |
| November 30, 2003 | 1,455,688 | 1,163,746 | 2,619,434 | \$2.60 |
|                   | =====     | =====     | =====     | =====  |

- (5) The information set forth in these condensed consolidated statements is unaudited and may be subject to normal year-end adjustments. The information reflects all adjustments which, in the opinion of management, are necessary to present a fair statement of the consolidated results of operations of Biomerica, Inc., for the periods indicated. It does not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flow in conformity with generally accepted accounting principles. Please see the Company's Annual Report on Form 10-KSB for the fiscal year ended May 31, 2003 for more detailed footnotes.
- (6) Consolidated results of operations for the interim periods covered by this report may not necessarily be indicative of results of operations for the full fiscal year.
- (7) Reference is made to Note 3 of the Notes to Consolidated Financial Statements contained in the Company's Annual Report on Form 10-KSB for the fiscal year ended May 31, 2003, for a description of the investments in affiliates and consolidated subsidiaries.
- (8) Reference is made to Notes 5 & 11 of the Notes to Consolidated Financial Statements contained in the Company's Annual Report on Form 10-KSB for the fiscal year ended May 31, 2003, for information on commitments and contingencies.
- (9) Aggregate market value exceeded cost of available-for-sale securities by approximately \$12,705 at November 30, 2003.

11

(10) Earnings Per Share

-----

In February 1997, the Financial Accounting Standards Board ("FASB") issued Statement of Financial Accounting Standards (SFAS) No. 128, EARNINGS PER SHARE ("EPS"). SFAS No. 128 requires dual presentation of basic EPS and diluted EPS on the face of all income statements issued after December 15, 1997 for all entities with complex capital structures. Basic EPS is computed as net income divided by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities.

The computation of diluted loss per share excludes the effect of incremental common shares attributable to the exercise of outstanding common stock options and warrants because their effect was antidilutive due to losses incurred by the Company.

As of November 30, 2003, there was a total of 3,669,570 potential dilutive

## Edgar Filing: BIOMERICA INC - Form 10QSB

shares of common stock outstanding.

- (11) In June 2001, the FASB issued SFAS No. 143, "ACCOUNTING FOR ASSET RETIREMENT OBLIGATIONS", which requires that the fair value of a liability for an asset retirement obligation be recognized in the period in which it is incurred with the associated asset retirement costs being capitalized as a part of the carrying amount of the long-lived asset. SFAS No. 143 also includes disclosure requirements that provide a description of asset retirement obligations and reconciliation of changes in the components of those obligations. The statement is effective for fiscal years beginning after June 15, 2002. The Company does not expect the adoption of SFAS No. 143 to have a material effect on the Company's consolidated financial position or results of operations.

In June 2002, the FASB issued SFAS No. 146, "ACCOUNTING FOR COSTS ASSOCIATED WITH EXIT OR DISPOSAL ACTIVITIES," which updates accounting and reporting standards for personnel and operational restructurings. The Company was required to adopt SFAS No. 146 for exit, disposal or other restructuring activities that are initiated after December 31, 2002, with early application encouraged. The Company adoption of SFAS No. 146 did not have a material effect on the Company's consolidated financial position or results of operations.

In April 2003, SFAS No. 149, "AMENDMENT OF STATEMENT 133 ON DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES" was issued. This statement amends and clarifies financial accounting and reporting for derivative instruments, including certain derivative instruments embedded in other contracts (collectively referred to as derivatives) and for hedging activities under SFAS No. 133, "Accounting for Derivative Instruments and Hedging Activities." This statement is effective for contracts entered into or modified after June 30, 2003. The adoption of this statement is not expected to have a significant effect on the Company's consolidated financial position or results of operations.

In May 2003, SFAS No. 150, "ACCOUNTING FOR CERTAIN FINANCIAL INSTRUMENTS WITH CHARACTERISTICS OF BOTH LIABILITIES AND EQUITY" was issued. This statement establishes standards for how an issuer classifies and measures certain financial instruments with characteristics of both liabilities and equity. This statement is effective for financial instruments entered into or modified after May 31, 2003. The adoption of SFAS No. 150 did not have a significant effect on the Company's consolidated financial position, results of operations, or cash flows.

In November 2002, FASB issued FASB Interpretation No. 45, "Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others" ("FIN 45"). FIN 45 clarifies that a guarantor is required to recognize, at the inception of a guarantee, a liability for the fair value of the obligation undertaken in issuing the

12

guarantee. The initial recognition and initial measurement provisions of FIN 45 are applicable on a prospective basis to guarantees issued or modified after December 31, 2002. The disclosure requirements of FIN 45 are applicable for financial statements of interim periods ending after December 15, 2002. The adoption of FIN 45 did not have a material impact on the Company's financial position, results of operations or cash flows.

In January 2003, FASB issued FASB Interpretation No. 46, "Consolidation of Variable Interest Entities" ("FIN 46"). This interpretation clarifies the

## Edgar Filing: BIOMERICA INC - Form 10QSB

application of Accounting Research Bulletin No. 51, "Consolidated Financial Statements," relating to consolidation of certain entities. FIN 46 will require identification of the Company's participation in variable interests entities ("VIEs"), which are defined as entities with a level of invested equity that is not sufficient to fund future activities to permit them to operation on a stand-alone basis, or whose equity holders lack certain characteristics of a controlling financial interest. For entities indentified as VIEs, FIN 46 sets forth a model to evaluate potential consolidation based on an assessment of which party to the VIE, if any, bears a majority of the exposure to its expected losses, or stands to gain from a majority of its expected returns. FIN 46 also sets forth certain disclosures regarding interests in VIEs that are deemed significant, even if consolidation is not required. The adoption of FIN 46 did not have a material impact on the Company's financial position, results of operations or cash flows.

- (12) Financial information about foreign and domestic operations and export sales is as follows:

|  | For the Six Months Ended |             |
|--|--------------------------|-------------|
|  | 11/30/03                 | 11/30/02    |
|  | -----                    | -----       |
| Revenues from sales to unaffiliated customers: |                          |             |
| United States                                  | \$2,168,000              | \$2,362,000 |
| Asia   | 100,000                  | 117,000     |
| Europe   | 1,196,000                | 954,000     |
| South America                                  | 248,000                  | 167,000     |
| Oceania  | 286,000                  | 208,000     |
| Other  | 436,000                  | 418,000     |
|  | -----                    | -----       |
|  | \$4,434,000              | \$4,226,000 |
|  | =====                    | =====       |

No other geographic concentrations exist where net sales exceed 10% of total net sales.

- (13) Pursuant to a decision by the Nasdaq Listing Qualifications Panel, the Company's common stock was delisted from the Nasdaq Stock Market effective June 20, 2002, for failure to comply with the net tangible assets or shareholders' equity requirements as set forth in Marketplace Rule 4310(c)(2)(B). The Company's securities were immediately eligible to trade on The OTC Bulletin Board and are traded under the symbol BMRA.OB.
- (14) Lancer has a \$400,000 line of credit with a financial institution, which expires January 24, 2004. Borrowings are made at prime plus 2.0%, in no event less than 8.0%, (8.0% at November 30, 2003), and are limited to 80% of accounts receivable less than 90 days old with a liquidity factor of 94%. The outstanding balance at November 30, 2003 was \$0 and the unused portion available was approximately \$326,000.

The line of credit is collateralized by substantially all the assets of Lancer, including inventories, receivables, and equipment. The lending agreement for the line of credit requires, among other things, that Lancer maintain a tangible net worth ratio of \$2,100,000 and that receivables' payments be sent to a controlled lockbox. In addition to interest, a management fee of .25% of the average monthly outstanding loan balance and an unused balance fee of .0425% on the average monthly unused portion available are required. Lancer is not required to maintain compensating balances in connection with this lending agreement. Proceeds from this line cannot be used to support the operations of Biomerica.

In October 2003 the line of credit was extended to January 24, 2004 by GE Capital Healthcare Financial Services so that Lancer could explore other financing options. An agreement with another financing institution is in the process of being finalized.

Biomerica entered into an agreement for a line of credit agreement on September 12, 2000 with a shareholder whereby the shareholder would loan to the Company, as needed, up to \$500,000 for working capital needs. The line of credit bore interest at 8%, was secured by accounts receivable and inventory, and expired September 13, 2003. The outstanding principal and interest on September 12, 2003 was \$337,835, including principal of \$288,050 and interest of \$48,985, all of which was converted into a note payable bearing interest at 8% with interest and principal due monthly. The monthly payments required to pay the loan off in four years would be \$8,248. The Company is currently paying \$7,200 per month toward interest and principal. The terms of the note are currently being negotiated. The remaining unpaid principal and interest, if any, are due September 12, 2007. The note is secured by inventory and accounts receivable of Biomerica.

- (15) In June 2003, the Company issued 202,000 shares of restricted common stock in a private placement to insiders and qualified investors. The stock was sold at \$.25 per share and had one warrant for the purchase of restricted common stock attached to each share of common stock purchased. During the three months ended August 31, 2003, \$48,080 was recorded as compensation expense for the excess in the market value of the issued common stock and warrants over the consideration received. The warrants vest immediately, expire in five years, and are exercisable at \$.25 per share.

On June 2, 2003, Lancer granted 52,500 stock options to purchase shares of Lancer common stock at an exercise price of \$.43 per share to directors of the Lancer for services rendered. The options vest over two years and have a term of five years.

On June 2, 2003, Lancer granted 75,000 stock options to purchase shares of Lancer common stock at an exercise price of \$.43 per share to its Chief Executive Officer in lieu of salary. The options vest over three years and have a term of five years.

On June 2, 2003, Lancer granted 120,000 stock options to purchase shares of the Lancer's common stock at an exercise price of \$.43 per share as pursuant to terms of the Employment agreement between Lancer and Dan Castner, the Vice President of Sales and Marketing. The options vest over four years and have a term of five years.

- (16) Reportable business segments for the six months and quarter ended November 30, 2003 and 2002 are as follows:

|                      | Six Months         |                    | Three Months       |                    |
|----------------------|--------------------|--------------------|--------------------|--------------------|
|                      | Ended November 30, | Ended November 30, | Ended November 30, | Ended November 30, |
|                      | 2003               | 2002               | 2003               | 2002               |
| -----                |                    |                    |                    |                    |
| Domestic sales:      |                    |                    |                    |                    |
| Orthodontic products | \$1,518,000        | \$1,566,000        | \$ 784,000         | \$ 812,000         |
| =====                |                    |                    |                    |                    |

Edgar Filing: BIOMERICA INC - Form 10QSB

|                             |             |             |            |            |
|-----------------------------|-------------|-------------|------------|------------|
| Medical diagnostic products | \$ 650,000  | \$ 796,000  | \$ 256,000 | \$ 269,000 |
| =====                       |             |             |            |            |
| Foreign sales:              |             |             |            |            |
| Orthodontic products        | \$1,366,000 | \$1,224,000 | \$ 782,000 | \$ 693,000 |
| =====                       |             |             |            |            |
| Medical diagnostic products | \$ 900,000  | \$ 640,000  | \$448,000  | \$ 363,000 |
| =====                       |             |             |            |            |

14

|   | Six Months<br>Ended November 30, |              | Three Months<br>Ended November 30, |              |
|---|----------------------------------|--------------|------------------------------------|--------------|
|   | 2003                             | 2002         | 2003                               | 2002         |
| -----                                     |                                  |              |                                    |              |
| Net sales:                                |                                  |              |                                    |              |
| Orthodontic products                      | \$2,884,000                      | \$2,790,000  | \$1,566,000                        | \$1,505,000  |
| Medical diagnostic products               | 1,550,000                        | 1,436,000    | 704,000                            | 632,000      |
| -----                                     |                                  |              |                                    |              |
| Total                                     | \$4,434,000                      | \$4,226,000  | \$2,270,000                        | \$2,137,000  |
| =====                                     |                                  |              |                                    |              |
| Operating (loss) income:                  |                                  |              |                                    |              |
| Orthodontic products                      | \$ (147,000)                     | \$ (20,000)  | \$ (2,000)                         | \$ 25,000    |
| Medical diagnostic products               | (293,000)                        | (274,000)    | (127,000)                          | (170,000)    |
| -----                                     |                                  |              |                                    |              |
| Total                                     | \$ (440,000)                     | \$ (294,000) | \$ (129,000)                       | \$ (145,000) |
| =====                                     |                                  |              |                                    |              |
| Operating loss from discontinued segment: |                                  |              |                                    |              |
| ReadyScript                               | \$ 2,944                         | \$ 38,531    | \$ 3,020                           | \$ 14,437    |
| -----                                     |                                  |              |                                    |              |
| Total                                     | \$ 2,944                         | \$ 38,531    | \$ 3,020                           | \$ 14,437    |
| =====                                     |                                  |              |                                    |              |
| Domestic long-lived assets:               |                                  |              |                                    |              |
| Orthodontic products                      | \$ 317,000                       | \$ 52,000    |                                    |              |
| Medical diagnostic products               | 137,000                          | 184,000      |                                    |              |
| -----                                     |                                  |              |                                    |              |
| Total                                     | \$ 454,000                       | \$ 236,000   |                                    |              |
| =====                                     |                                  |              |                                    |              |
| Foreign long-lived assets:                |                                  |              |                                    |              |
| Orthodontic products                      | \$ 122,000                       | \$ 19,000    |                                    |              |
| Medical diagnostic products               | 17,000                           | --           |                                    |              |
| -----                                     |                                  |              |                                    |              |
| Total                                     | \$ 139,000                       | \$ 19,000    |                                    |              |
| =====                                     |                                  |              |                                    |              |
| Total assets:                             |                                  |              |                                    |              |
| Orthodontic products                      | \$ 3,622,000                     | \$3,532,000  |                                    |              |
| Medical diagnostic products               | 1,632,000                        | 1,465,000    |                                    |              |

Edgar Filing: BIOMERICA INC - Form 10QSB

|  |              |             |
|--|--------------|-------------|
| Total                                  | \$ 5,254,000 | \$4,997,000 |
| =====                                  |              |             |
| Depreciation and amortization expense: |              |             |
| Orthodontic products                   | \$ 25,000    | \$ 48,000   |
| Medical diagnostic products            | 32,000       | 25,000      |
| -----                                  |              |             |
| Total                                  | \$ 57,000    | \$ 73,000   |
| =====                                  |              |             |
| Capital expenditures:                  |              |             |
| Orthodontic products                   | \$ 227,000   | \$ 36,000   |
| Medical diagnostic products            | 18,000       | 25,000      |
| -----                                  |              |             |
| Total                                  | \$ 245,000   | \$ 61,000   |
| =====                                  |              |             |

The net sales as reflected above consist of sales of unaffiliated customers only as there were no significant intersegment sales during the quarter ended November 30, 2003 and 2002.

15

- (17) Pursuant to the terms of the employment agreement between Lancer and Dan Castner, the Vice President of Sales and Marketing of Lancer, dated May 20, 2003, Lancer agreed to pay Mr. Castner an annual base salary of \$135,000. In addition, Lancer granted Mr. Castner stock options on June 2, 2003, to purchase an aggregate of 120,000 shares of Lancer's common stock at an exercise price of \$.43 per share. The stock options have a term of five years and will vest over four years as follows: (i) 25% vesting on the first anniversary of the date of grant; (ii) 25% vesting on the second anniversary of the date of grant; (iii) the remaining 50% vesting as to one-twenty fourth (1/24th) per month each month thereafter for the next two years. Should Lancer be purchased by an affiliated third party, the options shall vest 100%.
- (18) In April 2003, Lancer de Mexico entered into a manufacturing subcontractor agreement with Biomerica, Inc., to provide manufacturing services in Mexicali, Mexico. The agreement requires reimbursement from Biomerica for discrete expenses such as payroll, shipping, and customs fees; lease and security deposits of approximately \$2,000 and \$1,100 per month, respectively; and service fees of approximately \$2,900 per month.
- (19) Under its bylaws, the Company has agreed to indemnify its officers and directors for certain events or occurrences arising as a result of the officer or director's serving in such capacity. The term of the indemnification period is for the officer's or director's lifetime. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. However, the Company has a directors and officer liability insurance policy that limits its exposure and enables it to recover a portion of any future amounts paid.

As a result of its insurance policy coverage, the Company believes the



## Edgar Filing: BIOMERICA INC - Form 10QSB

estimated fair value of these indemnification agreements is minimal and has no liabilities recorded for these agreements as of November 30, 2003. The Company enters into indemnification provisions under (i) its agreements with other companies in its ordinary course of business, typically with business partners, contractors, and customers, landlords and (ii) its agreements with investors. Under these provisions the Company generally indemnifies and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of the Company's activities or, in some cases, as a result of the indemnified party's activities under the agreement. These indemnification provisions often include indemnifications relating to representations made by the Company with regard to intellectual property rights. These indemnification provisions generally survive termination of the underlying agreement. In addition, in some cases, the Company has agreed to reimburse employees for certain expenses and to provide salary continuation during short-term disability. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. The Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the estimated fair value of these agreements is minimal. Accordingly, the Company has no liabilities recorded for these agreements as of November 30, 2003."

- (20) The Chief Executive Officer and Chief Financial Officer of Biomerica are not currently taking a cash salary. Their wages are being recorded as an administrative expense and reported as part of accrued wages on the balance sheet.
- (21) Included in accounts payable is \$115,699 due for rental of the Company's facilities according to the terms of the lease. All of this amount is past due.
- (22) CRITICAL ACCOUNTING POLICIES

The discussion and analysis of our financial condition and results of operations are based on the consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these consolidated financial statements requires estimates and assumptions that affect the reported amounts and disclosures.

We believe the following to be critical accounting policies as they require more significant judgments and estimates used in the preparation of our consolidated financial statements. Although we believe that our judgments and estimates are appropriate and correct, actual future results may differ from our estimates.

16

In general the critical accounting policies that may require judgments or estimates relate specifically to the recognition of revenue, the Allowance for Doubtful Accounts, Inventory Reserves for Obsolescence and Declines in Market Value, Impairment of Long-Lived Assets, Stock Based Compensation and Deferred Income Tax Valuation and Allowances.

We recognize product revenues when an arrangement exists, delivery has occurred, the price is determinable and collection is reasonably assured.

The Allowance for Doubtful Accounts is established for estimated losses resulting from the inability of our customers to make required payments.

## Edgar Filing: BIOMERICA INC - Form 10QSB

The assessment of specific receivable balances and required reserves is performed by management and discussed with the audit committee. We have identified specific customers where collection is probably and have established specific reserves, but to the extent collection is made, the allowance will be released. Additionally, of the financial condition of our customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. Reserves are provided for excess and obsolete inventory, which are estimated based on a comparison of the quantity and cost of inventory on hand to management's forecast of customer demand. Customer demand is dependent on many factors and requires us to use significant judgment in our forecasting process. We must also make assumptions regarding the rate at which new products will be accepted in the marketplace and at which customers will transition from older products to newer products. Once a reserve is established, it is maintained until the product to which it relates is sold or otherwise disposed of, even if in subsequent periods we forecast demand for the product.

In general, we are in a loss position for tax purposes, and have established a valuation allowance against deferred tax assets, as we do not believe it is likely that we will generate sufficient taxable income in future periods to realize the benefit of our deferred tax assets. Predicting future taxable income is difficult, and requires the use of significant judgment. At November 30, 2003, all of our deferred tax assets were reserved. Accruals are made for specific tax exposures and are generally not material to our operating results or financial position, nor do we anticipate material changes to these reserves in the near future.

We have adopted SFAS No. 123, "Accounting for Stock-Based Compensation," for Disclosure purposes. Under SFAS No. 123, we measure compensation for our stock-based employee compensation plan using the intrinsic value method prescribed in Accounting Principles Board ("APB") No. 25, "Accounting for Stock Issued to Employees" and its related interpretations. We provide pro forma disclosure of the effect on net income or loss as if the fair value based method prescribed in SFAS No. 123 has been applied in measuring compensation expense.

We have provided a full valuation reserve related to our substantial deferred tax assets. In the future, if sufficient evidence of our ability to generate sufficient future taxable income in certain tax jurisdictions becomes apparent, we may be required to reduce our valuation allowances, resulting in income tax benefits in our consolidated statement of operations. We evaluate the realizability of the deferred tax assets and assess the need for valuation allowance quarterly. The utilization of the net operating loss carryforwards could be substantially limited due to restrictions imposed under federal and state laws upon a change of ownership.

### (23) Risks and Uncertainties

License Agreements - Certain of the Company's sales of products are governed by license agreements with outside third parties. All of such license agreements to which the Company currently is a party, are for fixed terms which will expire after ten years from the commencement of the agreement or upon the expiration of the underlying patents. After the expiration of the agreements or the patents, the Company is free to use the technology that had been licensed. There can be no assurance that the Company will be able to obtain future license agreements as deemed necessary by management. The loss of some of the current licenses or the inability to obtain future licenses could have an adverse affect on the Company's financial position and operations. Historically, the Company has successfully obtained all the licenses it believed necessary to conduct its

business.

17

Distribution - The Company has entered into various exclusive and non-exclusive distribution agreements (the "Agreements") which generally specify territories of distribution. The agreements range in term from one to five years. The Company may be dependent upon such distributors for the marketing and selling of its products worldwide during the terms of these agreements. Such distributors are generally not obligated to sell any specified minimum quantities of the Company's product. There can be no assurance of the volume of product sales that may be achieved by such distributors.

Government Regulations - The Company's products are subject to regulation by the FDA under the Medical Device Amendments of 1976 (the "Amendments"). The Company has registered with the FDA as required by the Amendments. There can be no assurance that the Company will be able to obtain regulatory clearances for its current or any future products in the United States or in foreign markets.

European Community - The Company is required to obtain certification in the European Community to sell products in those countries. The certification requires the Company to maintain certain quality standards. The Company has been granted certification on certain products. However, there is no assurance that the Company will be able to retain its certification in the future.

Risk of Product Liability - Testing, manufacturing and marketing of the Company's products entail risk of product liability. The Company currently has product liability insurance. There can be no assurance, however, that the Company will be able to maintain such insurance at a reasonable cost or in sufficient amounts to protect the Company against losses due to product liability. An inability could prevent or inhibit the commercialization of the Company's products. In addition, a product liability claim or recall could have a material adverse effect on the business or financial condition of the Company.

18

MANAGEMENT'S DISCUSSION AND ANALYSIS OF  
FINANCIAL CONDITION AND SELECTED FINANCIAL DATA

CERTAIN INFORMATION CONTAINED HEREIN (AS WELL AS INFORMATION INCLUDED IN ORAL STATEMENTS OR OTHER WRITTEN STATEMENTS MADE OR TO BE MADE BY BIOMERICA) CONTAINS STATEMENTS THAT ARE FORWARD-LOOKING, SUCH AS STATEMENTS RELATING TO ANTICIPATED FUTURE REVENUES OF THE COMPANY AND SUCCESS OR CURRENT PRODUCT OFFERINGS. SUCH FORWARD-LOOKING INFORMATION INVOLVES IMPORTANT RISKS AND UNCERTAINTIES THAT COULD SIGNIFICANTLY AFFECT ANTICIPATED RESULTS IN THE FUTURE, AND ACCORDINGLY, SUCH RESULTS MAY DIFFER MATERIALLY FROM THOSE EXPRESSED IN ANY FORWARD-LOOKING STATEMENTS MADE BY OR ON BEHALF OF BIOMERICA. THE POTENTIAL RISKS AND UNCERTAINTIES INCLUDE, AMONG OTHERS, FLUCTUATIONS IN THE COMPANY'S OPERATING RESULTS. THESE RISKS AND UNCERTAINTIES ALSO INCLUDE THE SUCCESS OF THE COMPANY IN RAISING NEEDED CAPITAL, THE CONTINUAL DEMAND FOR THE COMPANY'S PRODUCTS, COMPETITIVE AND ECONOMIC FACTORS OF THE MARKETPLACE, AVAILABILITY OF RAW MATERIALS, HEALTH CARE REGULATIONS AND THE STATE OF THE ECONOMY. READERS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE HEREOF, AND THE COMPANY UNDERTAKES NO OBLIGATION TO

## Edgar Filing: BIOMERICA INC - Form 10QSB

UPDATE THESE FORWARD-LOOKING STATEMENTS.

### RESULTS OF OPERATIONS

Consolidated net sales for Biomerica were \$4,434,215 for the six months ended November 30, 2003 as compared to \$4,226,038 for the same period in the prior fiscal year. This represents an increase of \$208,177, or 4.9% for the six month period. Of this increase \$93,356 was attributable to an increase in sales at Lancer. Consolidated net sales for the quarter then ended were \$2,269,856 as compared to \$2,136,529 for the same period in the previous year. This represents an increase of \$133,327, or 6.2%. Of this quarterly increase \$60,748 was attributable to sales at Lancer. The increase in sales at Lancer was primarily attributable to increases in sales in Central and South America. Domestic sales at Lancer decreased by \$49,258 and \$28,778 for the six month and quarter, respectively. Increases in sales at Biomerica were a result of sales of new products and an increase in foreign sales.

Cost of sales as a percentage of sales increased from 69.9% to 70.8% for the six months remained consistent at 71.0% for the quarter. Lancer's cost of sales as a percentage of sales increased from 70.9% to 72.0% for the six months and for the quarter increased from 70.1% to 70.3%. These increases were attributable to increased production costs and reserve for obsolete inventory. Biomerica's cost of sales as a percentage of sales increased for the six months from 67.9% to 68.4%. For the quarter Biomerica's cost of sales decreased from 73.3% to 72.4%. The increase for the six month was due to the start up of the Mexico facility, whereas the decrease for the three months was attributable to lower wage costs.

Selling, general and administrative costs increased by \$137,004, or 9.4% for the six months and increased by \$18,762, or 2.7% for the quarter. Lancer had increased selling, general and administrative costs of \$29,565 for the six months and \$93,165 for the quarter. Lancer had increased labor costs in marketing which was partially offset by decreased labor and professional fees in the administrative department. Administrative expenses at Biomerica increased due to a variety of expense increases, such as consulting, utilities and insurance.

Research and development increased by \$31,547, or 28.6% for the six months and by \$5,083 for the three months. Lancer had an increase in research and development costs of \$28,679 and \$11,362 for the six and three months, respectively. These expenses were attributable to the development of a new product line. Biomerica had increased costs of \$2,868 and decreased costs of \$6,278 for the six and three months, respectively. The increase for the six months was due to higher wages and the decrease for the quarter was due to lower material costs.

19

For the six months ended November 30, 2003, other income of \$33,258 was realized as compared to \$51,992 in the prior year which was a result of the insurance claim settlement of \$47,981 for the theft of inventory at the Lancer Orthodontics Inc.'s Mexicali facility. For the three months, other income was \$26,247 as compared to \$3,942. The increase was primarily due to the sale of securities by Biomerica.

Interest expense decreased by \$2,324 (13.1%) for the six months compared to the previous year and by \$1,988 for the quarter. The decrease was primarily due to use of cash instead of line of credit at Lancer for part of the year.

Please refer to Note 3 in the Notes to the Consolidated Financial Statements in the Company's report on Form 10-KSB for the year ended May 31, 2003, for a more

## Edgar Filing: BIOMERICA INC - Form 10QSB

in-depth discussion of subsidiaries.

### LIQUIDITY AND CAPITAL RESOURCES

As of November 30, 2003, the Company had cash and available-for-sale securities in the amount of \$332,413 and working capital of \$2,460,835. Cash and working capital totaling \$224,237 and \$2,477,013 respectively, relates to the Lancer subsidiary. Lancer's line of credit restricts Biomerica's ability to draw on Lancer's resources and, as such, said cash, working capital and equity are not available to Biomerica.

The Company has suffered substantial recurring losses from operations over the last couple of years. The Company has funded its operations through debt and equity financings, and may have to do so in the future. ReadyScript operations were discontinued in May 2001 and Allergy Immuno Technologies was sold in May 2002. ReadyScript and Allergy Immuno Technologies were previously contributors to the Company's losses. The Company has reduced operating costs through certain cost reduction efforts and plans to concentrate on its core business in Lancer and Biomerica to increase sales. There can be no assurance that the Company will be able to become profitable, generate positive cash flow from operations or obtain the necessary equity or debt financing to fund operations in the future. Should the Company be unable to reduce costs adequately or should the Company be unable to secure additional financing, the result for the Company could be the inability to continue operations.

The Company will continue to have limited cash resources. Although the Company's management recognizes the imminent need to secure additional financing there can be no assurance that the Company will be successful in consummating any such transaction or, if the Company does consummate such transaction, that the terms and conditions of such financing will not be unfavorable to us.

Our independent certified public accountants have concluded that these factors, among others, raise substantial doubt as to the Company's ability to continue as a going concern for a reasonable period of time, and have, therefore modified their audit report on the Company's annual consolidated financial statements as of and for the year ended May 31, 2003 in the form of an explanatory paragraph describing the events that have given rise to this uncertainty. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result should the Company be unable to continue as a going concern.

These consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has operating and liquidity concerns due to historically reporting net losses and negative cash flows from operations. Biomerica's shareholder's line of credit expired September 13, 2003. The unpaid principal and interest of \$337,835 was converted into a note payable bearing interest at 8% and payable in monthly installments over four years. The monthly payments required to pay the loan off would be \$8,248 per month. The Company is currently making payments of \$7,200 per month. The terms of the note are currently being negotiated. The note is secured by inventory and accounts receivable.

20

During the six months ended November 30, 2003, the Company operations used cash of \$21,225. This compares to cash provided by operations of \$363,596 in the same period in the prior fiscal year. The Lancer subsidiary used cash in operations of \$53,281 during this fiscal year and provided cash of \$407,005 in the last fiscal year. Cash provided by financing activities was \$58,289, which resulted

## Edgar Filing: BIOMERICA INC - Form 10QSB

from a private placement of \$30,500, increase in shareholder loan of \$20,035, change in minority interest of \$6,180 and exercise of stock option of \$2,000.

The Company purchased \$244,948 in fixed assets during the first six month of this fiscal year. Of this, \$227,378 was a result of expenditures at the Lancer subsidiary.

The Chief Executive Officer and Chief Financial Officer of Biomerica are not currently taking a cash salary. Their wages are being recorded as an administrative expense and reported as part of accrued wages on the balance sheet.

Pursuant to a decision by the Nasdaq Listing Qualifications Panel, the Company's common stock was delisted from the Nasdaq Stock Market effective June 20, 2002, for failure to comply with the net tangible assets or shareholders' equity requirements as set forth in Marketplace Rule 4310(c)(2)(B). The Company's securities were immediately eligible to trade on the OTC Bulletin Board and are traded under the symbol BMRA.OB.

At November 30, 2003, Lancer had a \$400,000 line of credit with a financial Institution, which expires January 24, 2003. Borrowings are made at prime plus 2.0% (8.0% at November 30, 2003) and are limited to 80% of accounts receivable less than 90 days old with a liquidity factor of 94%. The outstanding balance at November, 2003 was \$0 and the unused portion available was approximately \$326,000.

The line of credit is collateralized by substantially all the assets of Lancer, including inventories, receivables, and equipment. The lending agreement for the line of credit requires, among other things, that Lancer maintain a tangible net worth ratio of \$2,100,000, which was met, and that receivables' payments be sent to a controlled lockbox. In addition to interest, a management fee of .25% of the average monthly outstanding loan balance and an unused balance fee of .0425% on the average monthly unused portion available are required. Lancer is not required to maintain compensating balances in connection with this lending agreement. Proceeds from this line cannot be used to support the operations of Biomerica.

In October 2003 the line of credit was extended to January 24, 2004 by GE Capital Healthcare Financial Services so that Lancer could explore other financing options. An agreement with another financing institution is in the process of being finalized.

Biomerica, Inc. entered into a line of credit agreement on September 12, 2000 with a shareholder whereby the shareholder would loan to the Company, as needed, up to \$500,000 for working capital needs. The line of credit expired September 12, 2003. The outstanding principal and interest on September 12, 2003 was \$337,835, including principal of \$288,850 and interest of \$48,985, all of which was converted into a note payable bearing interest at 8% with interest and principal due monthly. The remaining principal and interest, if any, are due September 12, 2007. The monthly payments required to pay the loan off in four years would be \$8,248 per month. The Company is currently paying \$7,200 per month. The terms of the note are currently being negotiated. The note is secured by inventory and accounts receivables of Biomerica.

### Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

You should read the following factors in conjunction with the factors discussed elsewhere in this and our other filings with the SEC and in materials incorporated by reference in these filings. The following is intended to highlight certain factors that may affect the financial condition and results of operations of Biomerica and are not meant to be an exhaustive discussion of risks that apply to companies such as Biomerica. Like other businesses,

## Edgar Filing: BIOMERICA INC - Form 10QSB

Biomerica is susceptible to macroeconomic downturns in the United States or

21

abroad, as were experiences in fiscal year 2002, that may affect the general economic climate and performance of Biomerica or its' customers. Aside from general macroeconomic downturns, the additional material factors that could affect future financial results include, but are not limited to: Terrorist attacks and the impact of such events; diminished access to raw materials that directly enter into our manufacturing process; shipping labor disruption or other major degradation of the ability to ship our products to end users; inability to successfully control our margins which are affected by many factors including competition and product mix; protracted shutdown of the U.S. Border due to an escalation of terrorist or counter terrorist activity; any changes in our business relationships with international distributors or the economic climate they operate in; any event that has a material adverse impact on our foreign manufacturing operations may adversely affect our operation as a whole; failure to manage the future expansion of our business could have an adverse affect on our revenues and profitability; possible costs in complying with government regulations and the delays in receiving required regulatory approvals or the enactment of new adverse regulations or regulatory requirements; numerous competitors, most of which have substantially greater financial and other resources than we do; potential claims and litigation brought by patients or medical professionals alleging harm caused by the use of or exposure to our products; quarterly variations in operating results caused by a number of factors, including business and industry conditions and other factors beyond our control. All of these factors make it difficult to predict operating results for any particular period.

In October 2003 the line of credit at Lancer was extended to January 24, 2004 by GE Capital Healthcare Financial Services so that Lancer could explore other financing options. An agreement with another financing institution is in the process of being finalized.

#### Item 4. CONTROLS AND PROCEDURES

The Company's Chief Executive Officer and Chief Financial Officer (the Company's principal executive officer and principal financial officer, respectively) have concluded, based on their evaluation as of November 30, 2003, that the design and operation of the Company's "disclosure controls and procedures" (as defined in rules 13a-15(e) under the Securities Exchange Act of 1934, as amended ("Exchange Act") are effective to ensure that information required to be disclosed by the Company in the reports filed or submitted by the Company under the Exchange Act is accumulated, recorded, processed, summarized and reported to the Company's management, including the Company's principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding whether or not disclosure is required.

During the quarter ended November 30, 2003, there were no changes in the Company's "internal controls over financial reporting" (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, the Company's internal controls over financial reporting.

22

## PART II. OTHER INFORMATION

## Edgar Filing: BIOMERICA INC - Form 10QSB

Item 1. LEGAL PROCEEDINGS. Inapplicable.

Item 2. CHANGES IN SECURITIES AND USE OF PROCEEDS. The following shares of Restricted common stock were issued during the six months Ended November 30, 2003:

| Date    | Title  | Amount  | Class or Persons Sold to       | Price Per Share | Total    |
|---------|--------|---------|--------------------------------|-----------------|----------|
| ----    | -----  | -----   | -----                          | -----           | -----    |
| 6/5/03  | common | 46,000  | qualified investors            | \$.25           | \$11,500 |
| 6/6/03  | common | 8,000   | qualified investor             | \$.25           | 2,000    |
| 6/9/03  | common | 8,000   | qualified investor             | \$.25           | 2,000    |
| 6/17/03 | common | 100,000 | qualified investor and insider | \$.25           | 25,000   |
| 6/23/03 | common | 20,000  | qualified investor             | \$.25           | 5,000    |
| 6/26/03 | common | 20,000  | qualified investor             | \$.25           | 5,000    |

The exemption relied upon for the issuance of the unregistered shares was that the shares were issued to qualified investors within the meaning of Securities and Exchange Commission Rule 501, Regulation D.

Item 3. DEFAULTS UPON SENIOR SECURITIES. Inapplicable.

Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

The 2002 Annual Meeting of the Company's stockholders was held on September 2, 2003. Two matters were voted on at the meeting, as set Forth in the proxy statement dated June 26, 2003, as filed with the Securities and Exchange Commission pursuant to Rule 14 under the Securities Act of 1934. The following summarizes the voting:

Proposal No. 1: Election of Directors

| Name     | For       | Votes Withheld |
|----------|-----------|----------------|
| ----     | ---       | -----          |
| Barbieri | 4,745,095 | 230,842        |
| Cano     | 4,745,095 | 230,842        |
| Irani    | 4,744,305 | 232,184        |
| Moore    | 4,744,705 | 231,232        |
| Orlando  | 4,745,095 | 230,842        |

All directors were elected.

Proposal No. 2: Proposal to Ratify and Approve the Company's 2002 Stock Incentive Plan

| For       | Against | Abstain |
|-----------|---------|---------|
| ---       | -----   | -----   |
| 1,870,275 | 400,481 | 70,483  |

Proposal No. 2 did not receive a plurality of the votes and therefore was not approved.

Item 5. OTHER INFORMATION. Inapplicable.

Item 6. EXHIBITS AND REPORTS ON FORM 8-K. Inapplicable.

(a) Exhibits

99.1 Certifications of Chief Executive Officer and Chief Financial Officer



Edgar Filing: BIOMERICA INC - Form 10QSB

pursuant To 18 U.S.C., Section 1350, as adopted pursuant to Section 302 and 906 of the Sarbanes-Oxley Act of 2002.

23

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has fully caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: January 20, 2004

BIOMERICA, INC.

By: /S/ Zackary S. Irani

-----  
Zackary S. Irani  
Chief Executive Officer

24